Hormonal
Semaglutide therapy significantly reduces systemic inflammation, as measured by C-reactive protein (CRP) levels, compared to placebo or other glucose-lowering drugs, regardless of whether the patient has type 2 diabetes or obesity without diabetes.
If you are taking semaglutide for diabetes or weight management, you can expect it to lower your systemic inflammation (measured by CRP). This benefit occurs whether you take the pill or the injection, and whether or not you have diabetes. This anti-inflammatory effect is likely a key reason why semaglutide reduces heart disease risk.
Overall, semaglutide therapy was associated with lower CRP index values compared to the placebo group (SMD −0.56; 95% CI −0.69 to −0.43, I2 92%) or the control group (SMD −0.45; 95% CI −0.68 to −0.23, I2 82%).
Why this rating
High-quality meta-analysis of 13 randomized clinical trials with over 26,000 patients, though with high heterogeneity (I2 92%).
Source
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Walter Massón et al. · Frontiers in Cardiovascular Medicine · 2024
DOI 10.3389/fcvm.2024.1379189
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →